Skip to main content
EQ
NASDAQ Life Sciences

Equillium Q2 Loss Narrows to $4.7M; Cash Runway Extended to 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$2.039
Mkt Cap
$127.085M
52W Low
$0.756
52W High
$3.54
52W Position info
170% above low
Off High info
42% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

EQ has more than doubled off its 52-week low of $0.756.

Summary

Equillium's Q2 loss beat expectations and cash runway extended to 2029, but significant warrant overhang remains.


Key Events · Earnings and Guidance · EQ

  • Q2 Loss Beats Consensus

    Net loss of $4.7 million ($0.04/share) versus consensus of $5.9 million ($0.05/share).

  • Cash Runway Extended to 2029

    Cash and equivalents of $57.2 million as of June 30, 2026, up from $30.3 million at year-end 2025, driven by the $35 million March private placement.

  • Significant Warrant Overhang

    48.5 million pre-funded warrants outstanding plus 35.1 million shares subject to milestone closing, representing potential dilution of over 130% of current shares outstanding.

  • Authorized Shares Doubled

    Stockholders approved an increase in authorized common shares from 200 million to 400 million on May 28, 2026.


Analysis · EQ · Life Sciences

Equillium reported a Q2 net loss of $4.7 million, beating consensus by $1.2 million, and disclosed $57.2 million in cash as of June 30, 2026. Management now expects the cash to fund operations into 2029, a significant extension from the prior 12-month guidance. The balance sheet was strengthened by a $35 million private placement in March 2026, but the company also carries substantial potential dilution from 48.5 million pre-funded warrants and 35.1 million shares subject to a milestone closing. The stock trades at $2.04, well below the $3.20 closing price used for option intrinsic value calculations at quarter-end.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EQ was trading at $2.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $127.1M. The 52-week trading range was $0.76 to $3.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EQ - Latest Insights

EQ
Nov 12, 2026, 4:20 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.34
Real-time Price: $1.34 info
Change: $0 (0%) info
Market Cap: $83.699M info
EQ
Oct 26, 2026, 5:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.29
Real-time Price: $1.34 info
Change: +$0.050 (+4%) info
Market Cap: $83.699M info
EQ
Oct 26, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.12
Real-time Price: $1.34 info
Change: +$0.2197 (+20%) info
Market Cap: $83.699M info
EQ
Oct 05, 2026, 5:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.42
Real-time Price: $1.34 info
Change: -$0.080 (-6%) info
Market Cap: $83.699M info
EQ
Oct 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $1.34 info
Change: -$0.170 (-11%) info
Market Cap: $83.699M info